CHRO
Channel Therapeutics Corporation
1.35
1 x 1.29
2 x 1.38
bid
ask
+
0.09
7.14%
04:00 PM
Ytd
1y
1.23
day range
1.41
undefined
52 week range
undefined
Open 1.40 Prev Close 1.26 Low 1.23 High 1.41 Mkt Cap N/A
Vol 193.12K Avg Vol 0.00 EPS N/A P/E N/A Forward P/E -0.58
Beta N/A Short Ratio 0.26 Inst. Own 7.07% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning N/A 50-d Avg N/A 200-d Avg N/A 1yr Est 8.50
Upgrade / Downgrade
Date Firm Action From To
2024-06-18 Alliance Global Partners Upgrade Buy
Profile
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Insider Holder
Date Name Relation Quantity Description
2024-02-20 DAVIS TODD CLIFTON Director 29.17K Conversion of Exercise of derivative security
2024-09-12 FRANCIS KNUETTEL II Chief Executive Officer 0.00 Purchase
2024-02-20 FRIEDBERG EZRA M Director 0.00 Conversion of Exercise of derivative security
2024-09-11 MALAMUT RICHARD Director 0.00 Purchase
Institution Ownership
Report Date Organization Position Value Percentage
2024-09-29 Avantax Planning Partners, Inc. 47.21K 30.21K 0.78%
2024-09-29 Two Sigma Securities, LLC 26.06K 16.68K 0.43%
2024-09-29 Wealth Enhancement Advisory Services, LLC 10.40K 6.66K 0.17%
2024-09-29 Tower Research Capital LLC (TRC) 259.00 165.00 0.00%
2024-09-29 Bank of America Corporation 11.00 7.00 0.00%
Fund Ownership
Report Date Organization Position Value Percentage
2024-10-30 Fidelity Extended Market Index Fund 5.01K 3.21K 0.08%
Split
Split Date
1 : 10 2025-07-02